https://www.skyrizihcp.com/dermatology 2026-03-18 https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/skyrizihcp-logo.png SKYRIZI® (risankizumab-rzaa) logo https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1005/Badge-NoNow.png Skyrizi single-dose pen. https://www.skyrizihcp.com/content/dam/remotedam/approved-assets/skyrizi/hcp/graphics/icon-number-one-combined.png SKYRIZI® is the #1 prescribed systemic by dermatologists for patients with psoriatic disease. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/character/at-week-16-man.png Man and dog. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/graphics/at-week-52-woman.png Woman in a bathing suit. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/US-SKZD-220396/callout-complete-pro.png COMPLETE Pro. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/graphics/home_baseballguy-desktop.png Man wearing baseball hat. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/skyrizi-complete-logo-white.png Skyrizi® Complete Logo. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-mobile.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-mobile.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-mobile.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline-chart-mobile.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/dermatology/site-map 2026-02-17 https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/skyrizihcp-logo.png SKYRIZI® (risankizumab-rzaa) logo https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-mobile.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-mobile.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-mobile.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline-chart-mobile.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/dermatology/psoriasis-efficacy 2026-03-18 https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/skyrizihcp-logo.png SKYRIZI® (risankizumab-rzaa) logo https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/pasi-90-ultimma-2.png ULTIMMA-2 Study: PASI 90 achieved by 81% of patients at 1 year. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/pasi-90-ultimma-2-mobile.png ULTIMMA-2 Study: PASI 90 achieved by 81% of patients at 1 year. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/charts/pasi-90-ultimma-1.png ULTIMMA-1 Study: PASI 90 achieved by 82% of patients at 1 year. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/charts/pasi-90-ultimma-1-mobile.png ULTIMMA-1 Study: PASI 90 achieved by 82% of patients at 1 year. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/pasi-90/pasi-90-group.png Before and after photos of SKYRIZI®- treated patients with moderate to severe plaque psoriasis from the UltIMMa-2 study with PASI 90 clearance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/pasi-90/pasi-90-front-1.png Baseline PASI of chest https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/pasi-90/pasi-90-back-1.png Baseline PASI of back https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/pasi-90/pasi-90-front-2.png 2 doses Week 16 PASI improvement of chest https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/pasi-90/pasi-90-back-2.png 2 doses Week 16 PASI improvement of back https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/pasi-90/pasi-90-front-3.png 5 doses Week 52 PASI improvement of chest https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/pasi-90/pasi-90-back-3.png 5 doses Week 52 PASI improvement of back https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/charts/pasi-100-ultimma-2.png ULTIMMA-2 Study: PASI 100 achieved by 60% of patients at 1 year. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/charts/pasi-100-ultimma-2-mobile.png ULTIMMA-2 Study: PASI 100 achieved by 60% of patients at 1 year. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/charts/pasi-100-ultimma-1.png ULTIMMA-1 Study: PASI 100 achieved by 56% of patients at 1 year. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/charts/pasi-100-ultimma-1-mobile.png ULTIMMA-1 Study: PASI 100 achieved by 56% of patients at 1 year. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/pasi-100/pasi-100-group.png Patient improvement with SKYRIZI®. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/pasi-100/pasi-100-front-1.png Baseline PASI of chest https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/pasi-100/pasi-100-back-1.png Baseline PASI of back https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/pasi-100/pasi-100-front-2.png 2 doses Week 16 PASI improvement of chest https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/pasi-100/pasi-100-back-2.png 2 doses Week 16 PASI improvement of back https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/pasi-100/pasi-100-front-3.png 5 doses Week 52 PASI improvement of chest https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/pasi-100/pasi-100-back-3.png 5 doses Week 52 PASI improvement of back https://www.skyrizihcp.com/content/dam/remotedam/approved-assets/skyrizi/hcp/graphics/icon-number-one-combined.png SKYRIZI® is the #1 prescribed systemic by dermatologists for patients with psoriatic disease. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/chart-pasi-90-100-desktop.jpg PASI 90 and PASI 100 achievement at week 304 in the open-label extension (OLE). https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/chart-pasi-90-100-mobile.jpg PASI 90 and PASI 100 achievement at week 304 in the open-label extension (OLE). https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/summer_update/divider-gray.png Line. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/baseline-front.png Before and After: Baseline PASI of chest. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/baseline-back.png Before and After: Baseline PASI of back. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/week4-front.png Before and After: 1 dose Week 4 PASI improvement of chest. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/week4-back.png Before and After: 1 dose Week 4 PASI improvement of back. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/week16-front.png Before and After: 2 doses Week 16 PASI improvement of chest. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/week16-back.png Before and After: 2 doses Week 16 PASI improvement of back. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/week52-front.png Before and After: 5 doses Week 52 PASI improvement of chest. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/patients/week52-back.png Before and After: 5 doses Week 52 PASI improvement of back. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-mobile.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline-chart-mobile.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/chart-safety-limmitless.jpg STUDY DESIGN - UltIMMa-1 and UltIMMa-2 (LIMMitless OLE). https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-mobile.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-mobile.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/nails-scalp-palmoplantar 2026-02-17 https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/skyrizihcp-logo.png SKYRIZI® (risankizumab-rzaa) logo https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/challenging-areas-scalp-iga-0-1-desktop.png 61 percent of patients treated with SKYRIZI® achieved completely clear or almost clear skin on their scalp at week 16. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/challenging-areas-pssi-desktop.png 53 percent of SKYRIZI® patients achieved PSSI 90 at week 16. 45 percent of SKYRIZI® patients achieved PSSI 100 at week 16. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-challenging-areas-scalp-with-nrs-desktop.png 50 percent of patients treated with SKYRIZI® reported a 4-point or greater reduction of scalp psoriasis itch at week 16. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-challenging-areas-genital-spga-g-0-1-desktop.png 69 percent of patients treated with SKYRIZI® achieved completely clear or almost clear skin in the genital area at week 16. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-challenging-areas-genital-spga-g-0-desktop.png 49 percent of patients treated with SKYRIZI® achieved a clinically meaningful improvement from baseline in genital psoriasis itch at week 16. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/challenging-areas-ppIGA1-0-desktop.png After two doses, 33 percent of patients treated with SKYRIZI® met the primary endpoint of ppIGA 0/1. After five doses, 51 percent of patients treated with SKYRIZI® met the primary endpoint of ppIGA 0/1. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/challenging-areas-ppasi-desktop.png SKYRIZI® PPASI 75 and 90 rates at week 16 and 52. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-mobile.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline-chart-mobile.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/immprint-safety-data-desktop.png IMMprint SAFETY DATA AT WEEK 16 & WEEK 52. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/immprint-study-design-desktop.png STUDY DESIGN - IMMprint https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/immprint-study-design-mobile.png STUDY DESIGN - IMMprint https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/immprint-baseline-char-desktop.png SELECTED BASELINE CHARACTERISTICS IN Ps CLINICAL TRIAL - ­IMMprint. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/immprint-baseline-char-mobile.png SELECTED BASELINE CHARACTERISTICS IN Ps CLINICAL TRIAL - ­IMMprint. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-unlimmited-study-s-modal-desktop.png STUDY DESIGN - UnllMMited Study-S. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-unlimmited-study-s-modal-mobile.png STUDY DESIGN - UnllMMited Study-S. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-unlimmited-study-s-table-modal-desktop.png SELECTED BASELINE CHARACTERISTICS IN Ps CLINICAL TRIAL - ­UnllMMited Study-S. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-unlimmited-study-s-table-modal-mobile.svg SELECTED BASELINE CHARACTERISTICS IN Ps CLINICAL TRIAL - ­UnllMMited Study-S. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-un-study-g-safety-modal-desktop.png STUDY DESIGN - UnllMMited Study-G. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-un-study-g-safety-modal-mobile.png STUDY DESIGN - UnllMMited Study-G. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-un-study-g-baseline-modal-desktop.png SELECTED BASELINE CHARACTERISTICS IN Ps CLINICAL TRIAL - UnllMMited Study-G. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-un-study-g-baseline-modal-mobile.png SELECTED BASELINE CHARACTERISTICS IN Ps CLINICAL TRIAL - UnllMMited Study-G. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/chart-safety-limmitless.jpg STUDY DESIGN - UltIMMa-1 and UltIMMa-2 (LIMMitless OLE). https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-mobile.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-mobile.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/before-and-after 2026-02-17 https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/skyrizihcp-logo.png SKYRIZI® (risankizumab-rzaa) logo https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/before-after/patient-illinois-week-16.jpg Patient results after 2 doses of SKYRIZI® at Week 16. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/before-after/patient-illinois-week-0.jpg Patient condition before starting SKYRIZI® at Week 0. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/before-after/patient-newyork-week-16.jpg.jpg Patient results after 2 doses of SKYRIZI® at Week 16. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/before-after/patient-newyork-week-0.jpg Patient condition before starting SKYRIZI® at Week 0. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/before-after/patient-tennesse-week-16.jpg Patient results after 2 doses of SKYRIZI® at week 16. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/before-after/patient-tennesse-week-0.jpg Patient condition before starting SKYRIZI® at Week 0. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/before-after/patient-rhodeisland-week-16.jpg Patient results after 2 doses of SKYRIZI® at Week 16. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/before-after/patient-rhodeisland-week-0.jpg Patient condition before starting SKYRIZI® at Week 0. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/before-after/patient-sc-week-16.png Patient results after 2 doses of SKYRIZI® at Week 16. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/before-after/patient-sc-week-0.png Patient condition before starting SKYRIZI® at Week 0. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/before-after/patient-pennsylvania-week-16.png Patient results after 2 doses of SKYRIZI® at Week 16. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/before-after/patient-pennsylvania-week-0.png Patient condition before starting SKYRIZI® at Week 0. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/before-after/patient-texas-arm-week-16.png Patient results after 2 doses of SKYRIZI® at Week 16. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/before-after/patient-texas-arm-week-0.png Patient condition before starting SKYRIZI® at Week 0. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/before-after/patient-texas-leg-week-16.png Patient results after 2 doses of SKYRIZI® at Week 16. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/before-after/patient-texas-leg-week-0.png Patient condition before starting SKYRIZI® at Week 0. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/before-after/patient-texas-week-16.png Patient results after 2 doses of SKYRIZI® at Week 16. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/before-after/patient-texas-week-0.png Patient condition before starting SKYRIZI® at Week 0. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/before-after/week-16_image-1.jpg Patient condition before starting SKYRIZI® at Week 0. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/before-after/week-16_image-5.jpg Patient condition before starting SKYRIZI® at Week 0. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/before-after/week-16_image-3.jpg Patient condition before starting SKYRIZI® at Week 0. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/before-after/week-16_image-7.jpg Patient condition before starting SKYRIZI® at Week 0. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/before-after/patient-sc-thumbnail.jpg Patient condition before starting SKYRIZI® at Week 0. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/before-after/patient-pennsylvania-thumbnail.jpg Patient condition before starting SKYRIZI® at Week 0. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/before-after/patient-texas-arm-thumbnail.jpg Patient condition before starting SKYRIZI® at Week 0. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/before-after/patient-texas-leg-thumbnail.jpg Patient condition before starting SKYRIZI® at Week 0. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/before-after/patient-texas-thumbnail.jpg Patient condition before starting SKYRIZI® at Week 0. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/before-after/patient-illinois-week-52.jpg Patient results after 5 doses SKYRIZI® at Week 52. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/before-after/week-16_image-1.png Patient condition before starting SKYRIZI® at Week 0. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-mobile.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline-chart-mobile.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/chart-safety-limmitless.jpg STUDY DESIGN - UltIMMa-1 and UltIMMa-2 (LIMMitless OLE). https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-mobile.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-mobile.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-otezla 2026-02-17 https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/skyrizihcp-logo.png SKYRIZI® (risankizumab-rzaa) logo https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0622/charts/chart-vsotezla-pasi90.png SKYRIZI® PASI 90 Rates compared to OTEZLA®. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0622/charts/chart-vsotezla-pasi90-mobile.png SKYRIZI® PASI 90 Rates compared to OTEZLA®. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/chart-vsotezla-adverse-event-desktop.jpg Overview of treatment­-emergent adverse events through week 16 for SKYRIZI® and OTEZLA®. Adverse event, serious adverse event, any infection, serious infections, tuberculosis, hypersensitivity, malignancy, injection site reaction, nausea, diarrhea, headache, depression, IBD and oral candidiasis were considered. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/graphics/percentage-of-patients.jpeg Discontinuation rates for SKYRIZI® and OTEZLA®. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/graphics/percentage-of-patients-mobile.jpeg Discontinuation rates for SKYRIZI® and OTEZLA®. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-response-rates-dlqi-desktop.png DLQI 0/1 rates for SKYRIZI® and OTEZLA®. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-mobile.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline-chart-mobile.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0622/immpulse-data-otezla-study-design-desktop.png In the IMMpulse study design, Part A randomization was 1:2. In Arm 1, patients were given SKYRIZI®. In Arm 2, patients were given OTEZLA® for Part A (16 weeks). During Part B, randomization was 1:1 and patients in Arm 2a were given SKYRIZI® and in Arm 2b, patients were given OTEZLA®. In Arm 3a and 3b, rescue was offered to patients <PASI 50 at Week 28 or Week 40. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0622/immpulse-data-otezla-study-design-mobile.png In the IMMpulse study design, Part A randomization was 1:2. In Arm 1, patients were given SKYRIZI®. In Arm 2, patients were given OTEZLA® for Part A (16 weeks). During Part B, randomization was 1:1 and patients in Arm 2a were given SKYRIZI® and in Arm 2b, patients were given OTEZLA®. In Arm 3a and 3b, rescue was offered to patients <PASI 50 at Week 28 or Week 40. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0622/immpulse-data-otezla-baseline-desktop.png SKYRIZI® Selected Baseline Characteristics for IMMpulse SKYRIZI® Head to Head Data. Demographics, disease severity and treatment experience were considered. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0622/immpulse-data-otezla-baseline-mobile.png SKYRIZI® Selected Baseline Characteristics for IMMpulse SKYRIZI® Head to Head Data. Demographics, disease severity and treatment experience were considered. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/chart-safety-limmitless.jpg STUDY DESIGN - UltIMMa-1 and UltIMMa-2 (LIMMitless OLE). https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-mobile.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-mobile.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-sotyktu 2026-02-17 https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/skyrizihcp-logo.png SKYRIZI® (risankizumab-rzaa) logo https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/marquees/hero-figure_psefficacy-sky-vs-sot.png Man on a paddle board. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-vs-sotyktu-pasi90.png SKYRIZI® PASI 90 Rates compared to SOTYKTU®. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-vs-sotyktu-pasi90-mobile.png SKYRIZI® PASI 90 Rates compared to SOTYKTU®. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-vs-sotyktu-adverse-event-desktop.png Overview of treatment­-emergent adverse events through week 16 for SKYRIZI® and SOTYKTU®. Adverse event, serious adverse event, any infection, serious infections, tuberculosis, hypersensitivity, malignancy, injection site reaction, nausea, diarrhea, headache, depression, IBD and oral candidiasis were considered. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/graphics/sotyktu-percentage-of-patients.png Discontinuation rates for SKYRIZI® and SOTYKTU®. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/graphics/sotyktu-percentage-of-patients-mobile.png Discontinuation rates for SKYRIZI® and SOTYKTU®. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/sotyktu-chart-response-rates-dlqi-desktop.png DLQI 0/1 rates for SKYRIZI® and SOTYKTU®. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-mobile.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline-chart-mobile.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-immpact-study-safety-modal-desktop.png STUDY DESIGN - IMMpactful. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-immpact-study-safety-modal-mobile.png STUDY DESIGN - IMMpactful. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-immpact-baseline-safety-modal-desktop.png SELECTED BASELINE CHARACTERISTICS IN Ps CLINICAL TRIAL - ­IMMpactful. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-immpact-baseline-safety-modal-mobile.png SELECTED BASELINE CHARACTERISTICS IN Ps CLINICAL TRIAL - ­IMMpactful. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/chart-safety-limmitless.jpg STUDY DESIGN - UltIMMa-1 and UltIMMa-2 (LIMMitless OLE). https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-mobile.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-mobile.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-cosentyx 2026-02-17 https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/skyrizihcp-logo.png SKYRIZI® (risankizumab-rzaa) logo https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/charts/chart-vscosentyx-primary.jpg SKYRIZI® demonstrated superior rates of PASI 90 at Week 52. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/charts/chart-vscosentyx-primary-mobile.jpg SKYRIZI® demonstrated superior rates of PASI 90 at Week 52. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/charts/chart-vscosentyx-secondary.jpg SKYRIZI® demonstrated superior rates of PASI 100 and sPGA 0/1 at Week 52. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/charts/chart-vscosentyx-secondary-mobile.png SKYRIZI® demonstrated superior rates of PASI 100 and sPGA 0/1 at Week 52. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-mobile.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline-chart-mobile.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immerge.jpg Study Design - IMMerge https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immerge-mobile.jpg Study Design - IMMerge https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immerge-baseline.jpg SKYRIZI® Selected Baseline Characteristics for IMMerge SKYRIZI® Head to Head Data https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immerge-baseline-mobile.jpg SKYRIZI® Selected Baseline Characteristics for IMMerge SKYRIZI® Head to Head Data https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/chart-safety-limmitless.jpg STUDY DESIGN - UltIMMa-1 and UltIMMa-2 (LIMMitless OLE). https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-mobile.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-mobile.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-humira 2026-02-17 https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/skyrizihcp-logo.png SKYRIZI® (risankizumab-rzaa) logo https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/chart-vshumira-a.jpg Chart depicting 72% of SKYRIZI® patients achieved PASI 90 vs 47% of HUMIRA patients (NRI). https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/chart-vshumira-a-mobile.jpg Chart depicting 72% of SKYRIZI® patients achieved PASI 90 vs 47% of HUMIRA patients (NRI). https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/chart-vshumira-b.jpg Chart depicting 66% of SKYRIZI® patients achieved PASI 90 vs 21% of HUMIRA patients (NRI). https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/chart-vshumira-b-mobile.jpg Chart depicting 66% of SKYRIZI® patients achieved PASI 90 vs 21% of HUMIRA patients (NRI). https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/vshumira-parta-PASI100-chart.png Chart depicting 40% of SKYRIZI® patients achieved complete clearance (PASI 100) vs 23% of Humira patients (NRI). https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/vshumira-parta-PASI100-chart-mobile.png Chart depicting 40% of SKYRIZI® patients achieved complete clearance (PASI 100) vs 23% of Humira patients (NRI). https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/vshumira-partb-PASI100-chart.png Chart depicting 40% of Skyrizi patients achieved complete clearance (PASI 100) vs 7% of Humira patients (NRI) at week 44. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/vshumira-partb-PASI100-chart-mobile.png Chart depicting 40% of Skyrizi patients achieved complete clearance (PASI 100) vs 7% of Humira patients (NRI) at week 44. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-mobile.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline-chart-mobile.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent.jpg SKYRIZI® Study Design for IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-mobile.jpg SKYRIZI® Study Design for IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/chart-safety-limmitless.jpg STUDY DESIGN - UltIMMa-1 and UltIMMa-2 (LIMMitless OLE). https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-mobile.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-stelara 2026-02-17 https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/skyrizihcp-logo.png SKYRIZI® (risankizumab-rzaa) logo https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-vsstelara-hero-mobile.png Chart depicting SKYRIZI® efficacy vs. STELARA® (ustekinumab) at Week 16 in ULTIMMA-1 and ULTIMMA-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-vsstelara-bottom-mobile.png Chart depicting SKYRIZI® efficacy vs. STELARA® (ustekinumab) at Week 16 in ULTIMMA‐1 and ULTIMMA‐2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-vsstelara-switch.png Chart depicting 73% of patients achieved PASI 90 after 1 dose at Week 12 of SKYRIZI®. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-vsstelara-switch-mobile.png Chart depicting 73% of patients achieved PASI 90 after 1 dose at Week 12 of SKYRIZI®. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-vsstelara-stay.png Chart depicting 86% of patients achieved PASI 90 at Week 52 and 87% at week 136 who started and remained on SKYRIZI®. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-vsstelara-stay-mobile.png Chart depicting 86% of patients achieved PASI 90 at Week 52 and 87% at week 136 who started and remained on SKYRIZI®. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/open-label-chart-vsstelara.png Chart depicting 51% of patients achieved complete clearance (PASI 100) after 1 Dose (12 weeks) of SKYRIZI®. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/open-label-chart-vsstelara-mobile.png Chart depicting 51% of patients achieved complete clearance (PASI 100) after 1 Dose (12 weeks) of SKYRIZI®. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/open-label-chart-vsstelara-stay.png Chart depicts 61% of patients achieved complete clearance (PASI 100) at week 52 and 63% at week 136. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/open-label-chart-vsstelara-stay-mobile.png Chart depicts 61% of patients achieved complete clearance (PASI 100) at week 52 and 63% at week 136. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-mobile.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline-chart-mobile.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/chart-safety-limmitless.jpg STUDY DESIGN - UltIMMa-1 and UltIMMa-2 (LIMMitless OLE). https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-mobile.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-mobile.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/dermatology/psoriatic-arthritis-efficacy 2026-03-18 https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/skyrizihcp-logo.png SKYRIZI® (risankizumab-rzaa) logo https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/marquees/embrace-couple.png Man and woman hugging. https://www.skyrizihcp.com/content/dam/remotedam/approved-assets/skyrizi/hcp/charts/chart-acr20-placebo-keepsake1.png After 3 doses of SKYRIZI, 57% of patients achieved ACR20 response at week 24 VS placebo. https://www.skyrizihcp.com/content/dam/remotedam/approved-assets/skyrizi/hcp/charts/chart-acr20-placebo-keepsake2-mobile.png After 3 doses of SKYRIZI, 51% of patients achieved ACR20 response at week 24 VS placebo. https://www.skyrizihcp.com/content/dam/remotedam/approved-assets/skyrizi/hcp/charts/chart-acr205070-keepsake1.png KEEPsAKE-1 Study: ACR20/50/70 Response Rates compared to placebo up to week 244 (OLE). https://www.skyrizihcp.com/content/dam/remotedam/approved-assets/skyrizi/hcp/charts/chart-acr205070-keepsake1-mobile.png KEEPsAKE-1 Study: ACR20/50/70 Response Rates compared to placebo up to week 244 (OLE). https://www.skyrizihcp.com/content/dam/remotedam/wip/eversana/us-skzd-260038/hcp/charts/chart-acr205070-keepsake2.png KEEPsAKE-2 Study: ACR20/50/70 response rates compared to placebo up to week 244 (OLE). https://www.skyrizihcp.com/content/dam/remotedam/wip/eversana/us-skzd-260038/hcp/charts/chart-acr205070-keepsake2-mobile.png KEEPsAKE-2 Study: ACR20/50/70 response rates compared to placebo up to week 244 (OLE). https://www.skyrizihcp.com/content/dam/remotedam/wip/eversana/us-skzd-260038/images/dermatology/charts/chart-psa-joint-relief.-mobile.png KEEPsAKE 1 and KEEPsAKE 2: SKYRIZI® mean change from baseline in all acr components out to week 244. https://www.skyrizihcp.com/content/dam/remotedam/approved-assets/skyrizi/hcp/charts/chart-pain-reduction-keepsake1.png SKYRIZI® clinical trial data on MCID response. The data shows 61% of patients on SKYRIZI achieved MCID response at week 24, compared to 43% for placebo. A long-term, as-observed analysis indicates 85% of initial responders maintained this response at week 244. https://www.skyrizihcp.com/content/dam/remotedam/approved-assets/skyrizi/hcp/charts/chart-pain-reduction-keepsake2.png SKYRIZI® clinical trial data on MCID response. The data shows 54% of patients on SKYRIZI achieved MCID response at week 24, compared to 32% for placebo. A long-term analysis indicates 79% of initial responders maintained this response at week 244. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/graphics/callout-access-mobile.png Woman on beach. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/backgrounds/callout-resources-mobile.png Man standing on beach. https://www.skyrizihcp.com/content/dam/remotedam/approved-assets/skyrizi/hcp/charts/chart-enthesitis.png An NRI analysis shows a 48% response rate for SKYRIZI® at week 24 versus 35% for placebo. In a separate as-observed analysis, the response rate was 83% at week 244. https://www.skyrizihcp.com/content/dam/remotedam/approved-assets/skyrizi/hcp/charts/chart-dactylitis.png An NRI analysis shows a 68% response rate for SKYRIZI® at week 24 compared to 51% for placebo. A long-term, as-observed analysis shows the response rate was 97% at week 244. https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/access-treatment.png Savings card. https://www.skyrizihcp.com/content/dam/risahcp/images/icons/complete-coverate.png Checkmark. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immerge.jpg SKYRIZI® Study Design for IMMerge SKYRIZI® Head to Head Data https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immerge-mobile.jpg SKYRIZI® Study Design for IMMerge SKYRIZI® Head to Head Data https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immerge-baseline.jpg SKYRIZI® Selected Baseline Characteristics for IMMerge SKYRIZI® Head to Head Data https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immerge-baseline-mobile.jpg SKYRIZI® Selected Baseline Characteristics for IMMerge SKYRIZI® Head to Head Data https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1111/charts/chart-safety-keepsake-desktop.png Study design - KEEPsAKE-1 and KEEPsAKE-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1111/charts/chart-safety-keepsake-mobile.png Study design - KEEPsAKE-1 and KEEPsAKE-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-keepbase-desktop.jpeg SELECTED BASELINE CHARACTERISTICS IN PsA CLINICAL TRIALS. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chartkeepbasemobile.png SELECTED BASELINE CHARACTERISTICS IN PsA CLINICAL TRIALS. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-mobile.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-mobile.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-mobile.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline-chart-mobile.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/remotedam/approved-assets/skyrizi/hcp/charts/chart-acr205070-keepsake2-mobile.png KEEPsAKE-2 Study: ACR20/50/70 response rates compared to placebo up to week 244 (OLE). https://www.skyrizihcp.com/dermatology/dosing 2026-03-18 https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/skyrizihcp-logo.png SKYRIZI® (risankizumab-rzaa) logo https://www.skyrizihcp.com/content/dam/remotedam/approved-assets/skyrizi/hcp/graphics/dosing-reminder.png A daily treatment reminder with the text 'Take a Pill,' where the word 'pill' is crossed out. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/skyrizi-pen-big.png SKYRIZI® dosing pen. https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/logo-eou.png Ease of use certified by the Arthritis Foundation. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/graphics/callout-access-mobile.png Woman on beach. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/backgrounds/callout-resources-mobile.png Man standing on beach. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/global/pen-injection-video-thumbail.png How to Inject_150mg Pen https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/resource-video-thumbnail-2.png How to Inject_150mg PREFILLED SYRINGE https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-mobile.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-mobile.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-mobile.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline-chart-mobile.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/dermatology/dosing/pso-psa-injection-device 2026-02-17 https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/skyrizihcp-logo.png SKYRIZI® (risankizumab-rzaa) logo https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/skyrizi-pen-desktop.png 150 mg/mL SKYRIZI pen. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-mobile.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-mobile.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-mobile.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline-chart-mobile.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/dermatology/dosing/mechanism-of-action 2026-03-18 https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/skyrizihcp-logo.png SKYRIZI® (risankizumab-rzaa) logo https://www.skyrizihcp.com/content/dam/remotedam/approved-assets/skyrizi/hcp/graphics/graphic-moa-desktop.png Scientific diagram illustrating the mechanism of action for SKYRIZI. The image shows the humanized monoclonal antibody binding to the p19 subunit of IL-23, which blocks it from binding to its receptor. This action inhibits the release of inflammatory cytokines involved in Psoriasis (Ps) and Psoriatic Arthritis (PsA). https://www.skyrizihcp.com/content/dam/risahcp/images/icons/icon-notes.png Enrollment Icon. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/rheumatology/icons/icon-dollar.svg Savings Card Icon. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-mobile.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-mobile.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-mobile.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline-chart-mobile.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/dermatology/pso-psa-safety-profile 2026-02-17 https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/skyrizihcp-logo.png SKYRIZI® (risankizumab-rzaa) logo https://www.skyrizihcp.com/content/dam/remotedam/wip/eversana/us-skzd-260038/images/dermatology/charts/chart-Ps-wk-16-mobile.png Ps at week 16 across SKYRIZI®, STELARA®, HUMIRA®, and the placebo. https://www.skyrizihcp.com/content/dam/remotedam/wip/eversana/us-skzd-260038/images/dermatology/charts/chart-PsA-wk-24-mobile.png Any adverse event of interest from pooled trial data at week 24 for SKYRIZI® vs placebo in PsA. https://www.skyrizihcp.com/content/dam/risahcp/images/icons/safety.png Shield. https://www.skyrizihcp.com/content/dam/remotedam/wip/eversana/us-skzd-260038/images/dermatology/charts/chart-adverse-events-mobile.png Adverse events of interest in Ps in SKYRIZI® vs. STELARA® at 52 weeks. https://www.skyrizihcp.com/content/dam/remotedam/wip/eversana/us-skzd-260038/images/dermatology/charts/chart-Ps-9yr-data-mobile.png ADVERSE EVENTS OF INTEREST IN Ps AND PsA FOLLOWING LONG-TERM EXPOSURE UP TO ~9 YEARS OF EXPOSURE IN Ps ACROSS 20 TRIALS. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/safety-exposure-rates-in-psa-table.png ADVERSE EVENTS OF INTEREST IN Ps AND PsA FOLLOWING LONG-TERM EXPOSURE UP TO 4 YEARS OF EXPOSURE IN PsA ACROSS 4 TRIALS. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/icons/clearance-male.png Patient. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/icons/dosing.png Calendar. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-immpact-study-safety-modal-desktop.png STUDY DESIGN - IMMpactful. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-immpact-study-safety-modal-mobile.png STUDY DESIGN - IMMpactful. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-immpact-baseline-safety-modal-desktop.png SELECTED BASELINE CHARACTERISTICS IN Ps CLINICAL TRIAL - ­IMMpactful. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-immpact-baseline-safety-modal-mobile.png SELECTED BASELINE CHARACTERISTICS IN Ps CLINICAL TRIAL - ­IMMpactful. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-unlimmited-study-s-modal-desktop.png STUDY DESIGN - UnllMMited Study-S. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-unlimmited-study-s-modal-mobile.png STUDY DESIGN - UnllMMited Study-S. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-unlimmited-study-s-table-modal-desktop.png SELECTED BASELINE CHARACTERISTICS IN Ps CLINICAL TRIAL - ­UnllMMited Study-S. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-unlimmited-study-s-table-modal-mobile.svg SELECTED BASELINE CHARACTERISTICS IN Ps CLINICAL TRIAL - ­UnllMMited Study-S. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-un-study-g-safety-modal-desktop.png STUDY DESIGN - UnllMMited Study-G. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-un-study-g-safety-modal-mobile.png STUDY DESIGN - UnllMMited Study-G. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-un-study-g-baseline-modal-desktop.png SELECTED BASELINE CHARACTERISTICS IN Ps CLINICAL TRIAL - UnllMMited Study-G. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-un-study-g-baseline-modal-mobile.png SELECTED BASELINE CHARACTERISTICS IN Ps CLINICAL TRIAL - UnllMMited Study-G. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-mobile.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline-chart-mobile.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/chart-safety-limmitless.jpg STUDY DESIGN - UltIMMa-1 and UltIMMa-2 (LIMMitless OLE). https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-mobile.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-mobile.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1111/charts/chart-safety-keepsake-desktop.png Study design - KEEPsAKE-1 and KEEPsAKE-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1111/charts/chart-safety-keepsake-mobile.png Study design - KEEPsAKE-1 and KEEPsAKE-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chart-keepbase-desktop.jpeg SELECTED BASELINE CHARACTERISTICS IN PsA CLINICAL TRIALS. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/charts/chartkeepbasemobile.png SELECTED BASELINE CHARACTERISTICS IN PsA CLINICAL TRIALS. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/immprint-safety-data-desktop.png IMMprint SAFETY DATA AT WEEK 16 & WEEK 52. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/immprint-study-design-desktop.png STUDY DESIGN - IMMprint https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/immprint-study-design-mobile.png STUDY DESIGN - IMMprint https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/immprint-baseline-char-desktop.png SELECTED BASELINE CHARACTERISTICS IN Ps CLINICAL TRIAL - ­IMMprint. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/charts/immprint-baseline-char-mobile.png SELECTED BASELINE CHARACTERISTICS IN Ps CLINICAL TRIAL - ­IMMprint. https://www.skyrizihcp.com/dermatology/coverage-access 2026-03-18 https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/skyrizihcp-logo.png SKYRIZI® (risankizumab-rzaa) logo https://www.skyrizihcp.com/content/dam/remotedam/approved-assets/skyrizi/hcp/graphics/icon-number-one-combined.png SKYRIZI® is the #1 prescribed systemic by dermatologists for patients with psoriatic disease. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/skyrizi-complete-logo-blue.png Skyrizi® Complete Logo. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-mobile.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-mobile.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-mobile.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline-chart-mobile.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/dermatology/support 2026-03-18 https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/skyrizihcp-logo.png SKYRIZI® (risankizumab-rzaa) logo https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/logos/Skyrizi-Complete.svg SKYRIZI® Complete Logo https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0425/logos/logo-complete-pro.png SKYRIZI® Complete Logo https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/icons/icon-search-file.png Paper and magnifying glass https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/icons/icon-mail-pc.png Computer https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/icons/icon-email-alert.png Prior Authorization alert https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/icons/icon-call.png Phone https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/icons/app-skyrizi-complete.png Skyrizi® Complete app logo. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/logos/apple-app-store-logo.svg Apple App Store logo. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/logos/google-play-badge.svg Google Play store logo. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/misc/complete-pro-video-thumbnail.jpg Complete Pro Video Thumbnail https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-mobile.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-mobile.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-mobile.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline-chart-mobile.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/dermatology/support/forms-downloads 2026-02-17 https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/skyrizihcp-logo.png SKYRIZI® (risankizumab-rzaa) logo https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/resources_enrollment.svg Enrollment. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/resources_billing.svg Computer. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/resources_access.svg Savings Card. https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-0525/resources_pharmacies.svg Pharmacy. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/resources_support.jpg Woman receiving support. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/resources_pharmacies.svg Pharmacy. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/global/pen-injection-video-thumbail.png How to Inject_150mg Pen https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/resource-video-thumbnail-2.png How to Inject_150mg PREFILLED SYRINGE https://www.skyrizihcp.com/content/dam/risahcp/images/SKZD-ITS-1108/injection-pen-thumbnail.png Injection training tips for 150 mg/mL SKYRIZI pen. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/dermatology/graphics/injection-syringe-thumbnail.png Injection training tips for 150 mg/mL SKYRIZI prefilled syringe. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/icon-email-blue.png Email. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/icons/complete-coverate.png Checkmark. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-mobile.jpg Study design - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immvent-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMvent. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-mobile.jpg Study design - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-immhance-baseline-mobile.jpg SELECTED BASELINE CHARACTERISTICS - IMMhance. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-mobile.jpg SKYRIZI® Study Design for UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2. https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-1027/charts/chart-ultimma-baseline-chart-mobile.jpg SELECTED BASELINE CHARACTERISTICS - UltIMMa-1 and UltIMMa-2.